RxSight, Inc. (Nasdaq: RXST) has announced the transition of its Chief Financial Officer, Shelley Thunen, from her role. Thunen, who has been with the company for nearly a decade, will support the transition and remain with the company until the appointment of her successor or until January 31, 2026. Following the transition, she has agreed to continue supporting the company as a consultant.
Under Thunen's leadership, RxSight has achieved significant milestones, with over 1,100 Light Delivery Devices (LDDs) in the field and more than a quarter million procedures performed. Her contribution has been pivotal in guiding RxSight from a pre-commercial company to its present status.
RxSight's Chief Executive Officer and President, Ron Kurtz, expressed gratitude for Thunen's instrumental role in shaping the company's financial strategy, emphasizing her leadership and commitment. Andy Corley, the Chairman of the Board, also commended Thunen's judgment, integrity, and dedication, particularly during significant events such as the company's initial public offering in 2021.
RxSight, Inc. is an ophthalmic medical device company specializing in providing customized vision to patients following cataract surgery. The company's flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients following cataract surgery.
The company did not provide specific financial metrics in the press release. The market has reacted to these announcements by moving the company's shares -1.87% to a price of $12.08. If you want to know more, read the company's complete 8-K report here.
